{"id":"paclitaxel-pac","safety":{"commonSideEffects":[{"rate":"52–75%","effect":"Neutropenia"},{"rate":"49–60%","effect":"Peripheral neuropathy"},{"rate":"60%","effect":"Myalgia/arthralgia"},{"rate":"80%","effect":"Alopecia"},{"rate":"52%","effect":"Nausea/vomiting"},{"rate":"43%","effect":"Diarrhea"},{"rate":"2–4%","effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL3707398","moleculeType":"Unknown"},"_dailymed":{"setId":"4df3fda6-0b29-420e-ab91-81441ce914ed","title":"PACLITAXEL (PACLITAXEL (AIBUMIN-BOUND)) INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION [NINGBO SHUANGCHENG PHARMACEUTICAL CO., LTD]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paclitaxel is a microtubule-stabilizing agent that binds to the β-tubulin subunit of microtubules, preventing their normal dynamic instability. This stabilization disrupts mitotic spindle formation and cell division, leading to G2/M phase arrest and triggering apoptosis in rapidly dividing cancer cells. It is effective across multiple solid tumor types and hematologic malignancies.","oneSentence":"Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T06:42:17.249Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic carcinoma of the ovary"},{"name":"Breast cancer (metastatic and adjuvant)"},{"name":"Non-small cell lung cancer"},{"name":"Kaposi's sarcoma"},{"name":"Gastric adenocarcinoma"}]},"trialDetails":[{"nctId":"NCT04605913","phase":"PHASE1, PHASE2","title":"Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-04-01","conditions":"Pancreas Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma","enrollment":40},{"nctId":"NCT05449366","phase":"PHASE1, PHASE2","title":"Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2022-02-01","conditions":"Peritoneal Malignant Mesothelioma","enrollment":7},{"nctId":"NCT07009925","phase":"PHASE2","title":"Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2025-06","conditions":"Squamous Cell Lung Cancer","enrollment":38},{"nctId":"NCT03468335","phase":"PHASE3","title":"2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2018-03-31","conditions":"Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer","enrollment":151},{"nctId":"NCT03887130","phase":"PHASE2","title":"Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2007-03-27","conditions":"Breast Cancer","enrollment":152},{"nctId":"NCT03304210","phase":"PHASE1","title":"PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2017-09-16","conditions":"Peritoneal Carcinomatosis, Ovarian Cancer Stage IIIB, Ovarian Cancer Stage IIIC","enrollment":20},{"nctId":"NCT04729608","phase":"PHASE3","title":"Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer","status":"TERMINATED","sponsor":"Aravive, Inc.","startDate":"2021-04-22","conditions":"Platinum-resistant Ovarian Cancer","enrollment":366},{"nctId":"NCT01802749","phase":"PHASE3","title":"Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2013-11","conditions":"Recurrent Ovarian Cancer","enrollment":406},{"nctId":"NCT04584112","phase":"PHASE1","title":"A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-09-28","conditions":"Triple-Negative Breast Cancer","enrollment":83},{"nctId":"NCT03639246","phase":"PHASE1","title":"Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"Aravive, Inc.","startDate":"2018-12-06","conditions":"Ovarian Cancer","enrollment":53},{"nctId":"NCT03665441","phase":"PHASE3","title":"Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC","status":"COMPLETED","sponsor":"ERYtech Pharma","startDate":"2018-09-15","conditions":"Pancreatic Adenocarcinoma","enrollment":512},{"nctId":"NCT03057600","phase":"PHASE2","title":"Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)","status":"COMPLETED","sponsor":"Calithera Biosciences, Inc","startDate":"2017-05-01","conditions":"Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer","enrollment":52},{"nctId":"NCT02071862","phase":"PHASE1","title":"Study of the Glutaminase Inhibitor CB-839 in Solid Tumors","status":"COMPLETED","sponsor":"Calithera Biosciences, Inc","startDate":"2014-02","conditions":"Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer","enrollment":210},{"nctId":"NCT01362374","phase":"PHASE1","title":"Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-07-11","conditions":"Neoplasms","enrollment":122},{"nctId":"NCT02125136","phase":"PHASE2","title":"Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2014-11","conditions":"Ductal Adenocarcinoma of the Pancreas","enrollment":168},{"nctId":"NCT02001974","phase":"PHASE1","title":"Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2012-02-27","conditions":"Metastatic Breast Cancer","enrollment":33},{"nctId":"NCT01126216","phase":"PHASE3","title":"Reduced Radiotherapy With Pac/Cis vs Standard Radiotherapy With 5-FU/Cis in Locally Advanced Head and Neck Cancer","status":"TERMINATED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2010-06","conditions":"Head and Neck Cancer","enrollment":221},{"nctId":"NCT02845908","phase":"PHASE2","title":"POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC","status":"COMPLETED","sponsor":"Fujian Cancer Hospital","startDate":"2015-11","conditions":"Malignant Neoplasm of Stomach Stage IV","enrollment":90},{"nctId":"NCT01803282","phase":"PHASE1","title":"Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-03-29","conditions":"Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer","enrollment":236},{"nctId":"NCT00600340","phase":"PHASE3","title":"2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab","status":"COMPLETED","sponsor":"Central European Cooperative Oncology Group","startDate":"2008-04","conditions":"Metastatic Breast Cancer","enrollment":564},{"nctId":"NCT04155671","phase":"PHASE2","title":"POF Versus FOLFOX Plus IP Paclitaxel in AGC","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2019-12-01","conditions":"Gastric Cancer","enrollment":260},{"nctId":"NCT01893801","phase":"PHASE1, PHASE2","title":"Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA","status":"COMPLETED","sponsor":"Pancreatic Cancer Research Team","startDate":"2013-05","conditions":"Stage IV Pancreatic Cancer","enrollment":25},{"nctId":"NCT00768469","phase":"PHASE1","title":"Study Evaluating Safety And Tolerability, Solid Tumor","status":"COMPLETED","sponsor":"Puma Biotechnology, Inc.","startDate":"2008-10","conditions":"Advanced Malignant Solid Tumors","enrollment":10},{"nctId":"NCT03620461","phase":"","title":"Gemcitabine and Nabpaclitaxel in Metastatic Pancreatic Carcinoma.","status":"COMPLETED","sponsor":"Galician Research Group on Digestive Tumors","startDate":"2013-12-01","conditions":"Metastatic Pancreatic Cancer","enrollment":210},{"nctId":"NCT00762034","phase":"PHASE3","title":"A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-12","conditions":"Non-small Cell Lung Cancer","enrollment":939},{"nctId":"NCT00539331","phase":"PHASE1","title":"Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2007-09","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":6},{"nctId":"NCT00452803","phase":"PHASE2","title":"Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in N2 Positive IIIA Non Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2006-04","conditions":"Lung Cancer","enrollment":102}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Taxol"],"phase":"marketed","status":"active","brandName":"Paclitaxel (Pac)","genericName":"Paclitaxel (Pac)","companyName":"Aravive, Inc.","companyId":"aravive-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Paclitaxel is an antagonist that targets the transient receptor potential cation channel subfamily V member 1, acting as a vanilloid receptor antagonist. It is used to treat various types of cancer, including non-small cell lung cancer, metastatic pancreatic cancer, stage IV pancreatic cancer, and peritoneal carcinomatosis, often in combination with other treatments such as 5-FU, docetaxel, and enzalutamide.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}